Abstract
Introduction: Thromboprophylaxis in Orthopaedic practice has long been a debated issue. The recent NICE guidelines have recommended low molecular weight heparins (LMWH) for all orthopaedic patients, although a number of authors have highlighted the low risk of thromboembolism in foot and ankle practice. We looked at our series of total ankle replacements (TAR) to identify the incidence of thromboembolism and any complications associated with chemical thromboprophylaxis.
Methods: All patients who had undergone TAR were reviewed retrospectively. Risk factors according to the NICE guidelines were identified as was the type of chemical thromboprophylaxis, if given. Complications including thromboembolism, wound ooze, swelling and delay in discharge were recorded.
Results: There were 45 TAR’s in 45 patients. 20 patients (44%) had been given some form of chemical thromboprophylaxis. There were no cases of thromboembolism in either group. In the group receiving chemical thromboprophylaxis, nine patients (45%) had a wound complication. In the group receiving no chemical thromboprophylaxis only one patient (4%) had a wound complication.
Discussion: Thromboprophylaxis in total ankle replacement may significantly increase the risk of wound complications. We would recommend caution when prescribing chemical prophylaxis for patients undergoing total ankle replacement.
Correspondence should be addressed to: Mr Andrew H. N. Robinson, Editorial Secretary, Department of Trauma and Orthopaedics, BOX 37, Addenbrooke’s Hospital, Cambridge CB2 2QQ, England.
